Stock Price
P/E Ratio
Volume Traded Today
Dividend
52 Week High/low
Alnylam Pharmaceuticals Inc Market Cap
The Alnylam Pharmaceuticals Inc (ALNY) share price is expected to increase by 7.88% over the next year. This is based on calculating the average 12-month share price estimate provided by 18 stock analysts who have covered ALNY. Price targets range from $160.5 at the low end to $400 at the high end. The current analyst consensus for ALNY is a buy. Please note analyst price targets are not guaranteed and could be missed completely.
About 18 Wall Street analysts have assigned ALNY 13 buy ratings, 4 hold ratings, and 1 sell ratings. This means that analysts expect Alnylam Pharmaceuticals Inc to outperform the market. Keep in mind that these ratings are typically refreshed every quarter, underscoring the importance of conducting your own research on ALNY. Don't forget to include both technical and fundamental analysis, as well as staying informed on news that could influence these ratings, in your due diligence.
These are the latest 20 analyst ratings of ALNY.
|
Analyst/Firm |
Rating |
Price Target |
Change |
Date |
|---|---|---|---|---|
| Jessica Fye JP Morgan | Neutral | $280 | Maintains | Aug 26, 2024 |
| Patrick Trucchio HC Wainwright & Co. | Buy | $400 | Reiterates | Aug 20, 2024 |
| Salveen Richter Goldman Sachs | Buy | $370 | Upgrade | Aug 16, 2024 |
| Joseph Stringer Needham | Buy | $320 | Maintains | Aug 2, 2024 |
| Luca Issi RBC Capital | Outperform | $300 | Maintains | Aug 2, 2024 |
| Whitney Ijem Canaccord Genuity | Buy | $366 | Maintains | Aug 2, 2024 |
| David Lebovitz Citigroup | Buy | $342 | Maintains | Aug 2, 2024 |
| Tiago Fauth Wells Fargo | Equal-Weight | $233 | Maintains | Aug 2, 2024 |
| Gena Wang Barclays | Overweight | $295 | Maintains | Aug 2, 2024 |
| Gary Nachman Raymond James | Outperform | $275 | Maintains | Aug 2, 2024 |
| Salveen Richter Goldman Sachs | Neutral | $198 | Maintains | Aug 2, 2024 |
| Olivia Brayer Cantor Fitzgerald | Neutral | $220 | Maintains | Jul 22, 2024 |
| Michael Ulz Morgan Stanley | Equal-Weight | $255 | Maintains | Jul 12, 2024 |
| Whitney Ijem Canaccord Genuity | Buy | $357 | Maintains | Jul 8, 2024 |
| Jessica Fye JP Morgan | Neutral | $248 | Maintains | Jul 3, 2024 |
| Olivia Brayer Cantor Fitzgerald | Neutral | $150 | Reiterates | Jul 1, 2024 |
| Eliana Merle UBS | Buy | $288 | Maintains | Jun 28, 2024 |
| Luca Issi RBC Capital | Outperform | $265 | Maintains | Jun 27, 2024 |
| Paul Matteis Stifel | Buy | $295 | Maintains | Jun 27, 2024 |
B of A Securities | Buy | $295 | Maintains | Jun 25, 2024 |
When did it IPO
2004
Staff Count
2,100
Country
United States
Sector/Industry
Healthcare/Biotechnology
CEO
Dr. Yvonne L. Greenstreet M.B.A., MBChB
Market Cap
$35.98B
In 2023, ALNY generated $1.83B in revenue, which was a increase of 76.23% from the previous year. This can be seen as a signal that ALNY's business is growing, and its share price could be worth more in the future. However, if the company grows faster (or slower) than expected, this could also have a major impact on the future share price.
Revenue From 2020
Revenue From 2021
Revenue From 2022
Revenue From 2023
Thu, 12 Sep 2024
Sentiment - POSITIVE
Source - MarketBeat
Summary - Alnylam Pharmaceuticals (NASDAQ: ALNY) stock has gained 100% over the last two years, driven by rising expectations for a groundbreaking heart treatment.
Why It Matters - Alnylam Pharmaceuticals' stock has surged 100% due to optimism about a groundbreaking heart treatment, suggesting potential for further significant gains.
Thu, 12 Sep 2024
Sentiment - NEUTRAL
Source - WSJ
Summary - Obscure diseases may present significant growth opportunities for pharmaceutical companies, potentially leading to lucrative developments in niche markets.
Why It Matters - Obscure diseases can lead to lucrative markets for drug companies, potentially driving stock prices up and attracting investment in innovative treatments.
Mon, 02 Sep 2024
Sentiment - POSITIVE
Source - Zacks Investment Research
Summary - Alnylam shares data from the HELIOS-B study to seek label expansion for Amvuttra, targeting ATTR amyloidosis with cardiomyopathy treatment.
Why It Matters - Alnylam's study data could lead to a label expansion for Amvuttra, potentially increasing market share and revenue from treating ATTR amyloidosis, influencing stock value and investment decisions.
Fri, 30 Aug 2024
Sentiment - NEGATIVE
Source - Reuters
Summary - Alnylam Pharmaceuticals' shares dropped nearly 11% pre-market Friday after its heart drug data did not meet elevated investor expectations.
Why It Matters - Alnylam's stock drop indicates decreased confidence in its heart drug's potential, suggesting future revenue challenges and impacting overall market valuation.
Fri, 30 Aug 2024
Sentiment - NEGATIVE
Source - Investors Business Daily
Summary - Alnylam's stock fell after its heart disease treatment underperformed expectations in a lengthy study, impacting investor sentiment.
Why It Matters - Alnylam's stock drop signals concerns over its heart disease treatment's efficacy, potentially impacting future sales, market position, and investor confidence.
Fri, 30 Aug 2024
Sentiment - NEGATIVE
Source - Benzinga
Summary - Alnylam Pharmaceuticals' stock is down following the release of detailed results from the HELIOS-B Phase 3 study of vutrisiran for ATTR-CM, initially reported in June.
Why It Matters - Alnylam's stock decline indicates market reaction to clinical study results, which can affect future revenue potential and investor sentiment regarding the company's drug pipeline.
The information that Ticker Nerd provides is general in nature as it has been prepared without taking account of your objectives, financial situation or needs. It is not intended as legal, financial or investment advice and should not be construed or relied on as such. Ticker Nerd is for information purposes only. Ticker Nerd is not responsible for any damages or losses that may occur as a result of reliance on this information. Before making any commitment of a legal or financial nature you should seek advice from a qualified and registered legal practitioner or financial or investment adviser. All content, group, messaging, tweets, newsletter, article, and email created by Ticker Nerd is intended for educational and information purposes only, is not financial, investment, legal or tax advice, and is a restatement, summary or extract of other data and research reports that are widely distributed from sources such as, but not limited to, Bloomberg, Market Watch, Wall Street Journal, Google Finance, and Yahoo Finance. Ticker Nerd is not a registered financial, investment, legal or tax advisor and is not liable for any financial loss you may incur acting on any information provided by Ticker Nerd. By registering, you agree not to hold Ticker Nerd liable at any time or under any circumstances for your decisions, actions, or results.
